Proceedings from a series of 11 summer webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Dr Carla Casulo and Ms Jacklyn Gideon, including the following topics: Diffuse Large B-Cell Lymphoma Introduction (0:00) Case: A man in his mid-70s with advanced-stage diffuse large B-cell lymphoma —Carla Casulo, MD (5:00) Case: A woman in her mid-60s with high-grade, Stage IV diffuse large B-cell lymphoma — Jacklyn Gideon, MSN, AGPCNP-BC (21:04) Hodgkin Lymphoma Case: A woman in her mid-30s with advanced-stage Hodgkin lymphoma — Dr Casulo (22:52) Case: A man in his late 30s with relapsed/refractory classical Hodgkin lymphoma — Ms Gideon (34:21) Follicular Lymphoma Case: A woman in her mid-50s with recurrent Grade I-II follicular lymphoma – Dr Casulo (37:17) Case: A man in his late 60s with recurrent Grade IIIA follicular lymphoma – Ms Gideon (46:31) Mantle Cell Lymphoma Case: A man in his mid-60s with advanced-stage mantle cell lymphoma – Dr Casulo (50:11) NCPD information and select publications

Research To Practice | Oncology Videos

Hodgkin and Non-Hodgkin Lymphomas | Summer Oncology Nursing Series: Hodgkin and Non-Hodgkin Lymphomas — Session 1

Featuring perspectives from Dr Nathan H Fowler, Prof John G Gribben and Dr Brad S Kahl, including the following topics: Introduction (0:00) Choice of Front-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (6:04) Selection of a BTK Inhibitor for the Treatment of CLL (20:11) Second-Line Therapy for CLL (27:50) Third-Line Therapy for CLL; Ongoing Research: Combination Strategies, Noncovalent BTK Inhibitors, CAR T-Cell Therapy (35:46) Selection of First- and Second-Line Treatment for Follicular Lymphoma (43:13) Third-Line Therapy for Follicular Lymphoma: Tazemetostat, PI3K Inhibitors, CAR T-Cell Therapy  (49:33) CME information and select publications

Chronic Lymphocytic Leukemia and Follicular Lymphoma | Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Featuring slide presentations and related discussion from Dr Nathan H Fowler, Prof John G Gribben and Dr Brad S Kahl, including the following topics: Contemporary Treatment Planning for Patients with Chronic Lymphocytic Leukemia (CLL) — Prof John G Gribben, MD, DSc, FMedSci (0:00) Novel Investigational Agents and Strategies for Indolent Lymphoma and CLL — Brad S Kahl, MD (48:08) Modern Management of Follicular Lymphoma: Selection and Sequencing of Treatment — Nathan H Fowler, MD (1:13:37) CME information and select publications

Chronic Lymphocytic Leukemia and Follicular Lymphoma | Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia and Follicular Lymphoma (Faculty Presentations)

Featuring an interview with Dr Kristen Ciombor, including the following topics: Final overall survival from the Phase III KN177 study evaluating pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (mCRC) (0:00) Trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing mCRC: Final results from the DESTINY-CRC01 study (1:54) My Pathway HER2 basket study: Pertuzumab with trastuzumab for patients with HER2-positive advanced solid tumors in a large, tissue-agnostic cohort (3:49) Nivolumab with ipilimumab or nivolumab with chemotherapy versus chemotherapy alone as first-line treatment for advanced esophageal squamous cell carcinoma: First results from the CheckMate 648 study (6:38) First-line nivolumab with chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma: Expanded efficacy and safety data from the CheckMate 649 study (8:15) Adjuvant nivolumab for resected esophageal or GEJ cancer after neoadjuvant chemoradiation therapy: Expanded efficacy and safety analyses from the CheckMate 577 study (9:57) Trastuzumab deruxtecan in patients with HER2-positive advanced gastric or GEJ adenocarcinoma: Final overall survival results from the Phase II DESTINY-Gastric01 study (11:10) Pembrolizumab with trastuzumab and chemotherapy for HER2-positive metastatic gastric or GEJ cancer: Initial findings of the Phase III KEYNOTE-811 study (12:27) FIGHT: A Phase II study of bemarituzumab combined with modified FOLFOX6 as first-line therapy for FGFR2b-positive advanced gastric or GEJ adenocarcinoma (15:24) IMbrave150 trial: Exploratory analysis of the association between treatment response and overall survival among patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab compared to sorafenib (16:19) Updated results of a Phase Ib study of regorafenib with pembrolizumab for first-line treatment of advanced HCC  (17:36) Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Update of the FIGHT-202 study (18:39) NIFTY: A Phase II study of liposomal irinotecan in combination with fluorouracil and leucovorin for patients with metastatic biliary tract cancer after disease progression on gemcitabine/cisplatin (20:14) Preoperative chemoradiation therapy to improve overall survival for patients with pancreatic cancer: Long-term results of the Phase III PREOPANC trial (21:40) Efficacy and safety of zenocutuzumab in patients with advanced pancreatic cancer and other solid tumors harboring NRG1 fusions (22:54) CME information and select publications

Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Key Presentations on Gastrointestinal Cancers from the 2021 ASCO Annual Meeting

Featuring an interview with Dr Sara M Tolaney, including the following topics: Role of the Breast Cancer Index® in predicting benefit from extended aromatase inhibitor therapy for hormone receptor (HR)-positive breast cancer  (0:00) ADAPT HR-positive/HER2-negative trial: Prognostic utility of genomic assays, clinical factors and response to endocrine therapy for patients with high-risk luminal breast cancer (5:43) De-escalation of neoadjuvant chemotherapy in the treatment of early breast cancer — Clinical outcomes from the ADAPT HR-negative/HER2-positive trial (9:49) Effect of dose escalation on the tolerability of neratinib — Results from the CONTROL study (15:02) Phase II GeparNuevo study: Addition of durvalumab to neoadjuvant anthracycline/taxane therapy for early triple-negative breast cancer (17:13) Neoadjuvant talazoparib for patients with HER2-negative early breast cancer with germline BRCA1/2 mutations — Results from the Phase II NEOTALA study (21:53) Results from the Phase III OlympiA trial assessing adjuvant olaparib for patients with high-risk HER2-negative early breast cancer with germline BRCA1/2 mutations (23:02) Updated survival results from Phase III studies of CDK4/6 inhibitors in combination with hormonal therapy for HR-positive, HER2-negative advanced breast cancer (27:23) Long-term outcomes with alpelisib and fulvestrant for patients with HR-positive advanced breast cancer with PIK3CA mutations (30:58) Trastuzumab with endocrine therapy or chemotherapy as first-line treatment for HR-positive, HER2-positive metastatic breast cancer: Results from the SYSUCC-002 trial (33:20) Subgroup analysis of the DESTINY-Breast01 trial: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer and stable brain metastases (36:29) BEGONIA: A Phase Ib/II study of durvalumab combinations for advanced triple-negative breast cancer (39:49) CME information and select publications

Breast Cancer | Oncology Today with Dr Neil Love: Key Presentations on Breast Cancer from the 2021 ASCO Annual Meeting

Featuring an interview with Dr Jaffer Ajani, including the following topics: Evolving Therapeutic Landscape of Upper Gastrointestinal Tumors (0:00) Case: A Man in His Late 50s with PD-L1-Positive, HER2-Negative, Microsatellite-Stable Metastatic Adenocarcinoma of the Gastroesophageal Junction (29:01) Case: A Man in His Mid-40s with HER2-Positive, Metastatic Gastroesophageal Cancer (30:35) Clinical Data on TAS-102 in Gastric Cancer (33:24) Ramucirumab with Irinotecan as Second-line Therapy for Patients with Advanced Gastric Cancer — Phase III RAINBOW-Asia Study (37:24) CME information and select publications

Gastroesophageal Cancers | Oncology Today with Dr Neil Love: Gastroesophageal Cancers

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Virginia F Borges and Harold J Burstein, including the following topics: Introduction  Cases from the Community — HER2-Positive Breast Cancer Highlights of ASCO 2021 — Virginia F Borges, MD, MMSc and Harold J Burstein, MD, PhD Cases from the Community — HER2-Negative Breast Cancer Highlights of ASCO 2021 — Virginia F Borges, MD, MMSc and Harold J Burstein, MD, PhD CME information and select publications  

Breast Cancer | ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care Part 6: Breast Cancer

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in gynecologic cancers. Featuring perspectives from Drs Deborah K Armstrong and Krishnansu S Tewari, including the following topics: Introduction  Cases from the Community — Ovarian Cancer Highlights of ASCO 2021 — Deborah K Armstrong, MD Cases from the Community — Endometrial and Cervical Cancers Highlights of ASCO 2021 — Krishnansu S Tewari, MD CME information and select publications

Gynecologic Cancers | ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care Part 5: Gynecologic Cancers

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in gastrointestinal cancers. Featuring perspectives from Drs Thomas A Abrams and J Randolph Hecht, including the following topics: Introduction  Cases from the Community — Colorectal Cancer, Gastric/Gastroesophageal Junction Cancer Highlights of ASCO 2021 — J Randolph Hecht, MD Cases from the Community — Hepatocellular Carcinoma, Cholangiocarcinoma Highlights of ASCO 2021 — Thomas A Abrams, MD CME information and select publications

Gastrointestinal Cancers | ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care Part 4: Gastrointestinal Cancers

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas. Featuring perspectives from Drs John N Allan and Sonali M Smith, including the following topics: Introduction  Cases from the Community — CLL and Follicular Lymphoma Highlights of ASCO and EHA 2021 — John N Allan, MD Cases from the Community — Mantle Cell Lymphoma, Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma Highlights of ASCO and EHA 2021 — Sonali M Smith, MD CME information and select publications

Chronic Lymphocytic Leukemia and Lymphomas | ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care Part 3: Chronic Lymphocytic Leukemia and Lymphomas

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in genitourinary cancers. Featuring perspectives from Drs Arjun Balar and Robert Dreicer, including the following topics: Introduction  Cases from the Community — Prostate Cancer Highlights of ASCO 2021 — Robert Dreicer, MD, MS Cases from the Community — Renal Cell Carcinoma, Bladder Cancer Highlights of ASCO 2021 — Arjun Balar, MD CME information and select publications

Genitourinary Cancers | ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care Part 2: Genitourinary Cancers

Proceedings from a daylong multitumor educational webinar in partnership with the Texas Society of Clinical Oncology, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Justin F Gainor and Corey J Langer, including the following topics: Introduction  Cases from the Community — Non-Small Cell Lung Cancer, Small Cell Lung Cancer Highlights of ASCO 2021 — Corey J Langer, MD Cases from the Community — Metastatic Non-Small Cell Lung Cancer Highlights of ASCO 2021 — Justin F Gainor, MD CME information and select publications

Lung Cancer | ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care Part 1: Lung Cancer

Featuring slide presentations and related discussion from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics: Evolving Clinical Decision-Making for Patients with ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (0:00) Selection and Sequence of Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer — Hope S Rugo, MD (40:00) New Directions in the Treatment of Triple-Negative and Hereditary Breast Cancer — Melinda Telli, MD (1:39:16) CME information and select publications

ER-Positive and Triple-Negative Breast Cancer | Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of ER-Positive and Triple-Negative Breast Cancer (Faculty Presentations)

Featuring perspectives from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics: Introduction (0:00) Evolving Clinical Decision-Making for Patients with ER-Positive, HER2-Negative Localized Breast Cancer (7:33) Case: A postmenopausal woman in her mid-50s with ER-positive, PR-negative, HER2-negative pT1cN1 breast cancer — Ruth O’Regan, MD (12:57) Case: A woman in her early 40s with 6-cm ER-positive, HER2-negative localized breast cancer — Reshma Mahtani, DO (15:10) Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (34:44) Case: A woman in her mid-50s with ER-positive, PR-negative, HER2-negative mBC — Dr O’Regan (36:33) Case: A woman in her early 50s with ER-positive, HER2-negative mBC — Germline BRCA2 mutation — Dr Mahtani (41:58) Case: A woman in her late 30s with ER-positive, HER2-negative mBC — Germline BRCA1 mutation — Ann Partridge, MD, MPH (46:45) New Directions in the Treatment of Triple-Negative Breast Cancer (TNBC) (53:24) Case: A woman in her early 50s with metastatic TNBC — PD-L1-positive — Dr Partridge (55:50) CME information and select publications

ER-Positive and Triple-Negative Breast Cancer | Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Challenging Cases of ER-Positive and Triple-Negative Breast Cancer

Featuring an interview with Dr Arjun Balar, including the following topics: Phase III VISION study: Lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (PC) (0:00) Updated safety outcomes from the EORTC 1333/PEACE III trial: Effect of adding bone-protecting agents (3:44) First results from the Phase III PEACE 1 study evaluating abiraterone acetate with prednisone and/or local radiation therapy for de novo metastatic castration-sensitive PC (5:09) Update on darolutamide tolerability: Outcomes with aggressive hormonal therapy for high-risk localized PC  (7:35) Bladder-sparing therapy with pembrolizumab, gemcitabine and concurrent hypofractionated radiation therapy for muscle-invasive bladder cancer (MIBC) (9:17) Results from the Phase II HCRN GU16-257 trial: Gemcitabine/cisplatin with nivolumab and selective bladder sparing for patients with MIBC (12:00) Long-term outcomes from the KEYNOTE-052 trial assessing first-line pembrolizumab for cisplatin-ineligible patients with advanced urothelial cancer (15:02) First-line maintenance therapy with avelumab for advanced urothelial cancer: Subgroup analysis of the JAVELIN Bladder 100 trial (17:19) Phase III CheckMate 9ER trial: Outcomes by baseline disease characteristics with nivolumab and cabozantinib for advanced renal cell carcinoma (RCC)  (18:29) Results from the Phase III KEYNOTE-564 study assessing pembrolizumab as postnephrectomy adjuvant therapy for patients with RCC  (20:16) Pembrolizumab with axitinib as first-line therapy for advanced RCC: Results from a 42-month follow-up of the KEYNOTE-426 trial (22:26) Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel agents for patients with RCC (24:07) Expert perspectives on advances in the treatment of genitourinary cancers (26:30) CME information and select publications

Genitourinary Cancers | Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

hubhopper

Research To Practice | Oncology Videos

hubhopper